Buck Elizabeth, Wells James A
Sunesis Pharmaceuticals, 341 Oyster Point Boulevard, South San Francisco, CA 94080, USA.
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2719-24. doi: 10.1073/pnas.0500016102. Epub 2005 Feb 14.
A key question regarding the signaling mechanism for G protein-coupled receptors (GPCRs) is what triggers agonism versus antagonism. Peptide analogs derived from the chemokine, complement fragment 5 anaphylatoxin (C5a), can act as agonists or antagonists to the C5a receptor, a member of the GPCR family [Gerber, B. O., Meng, E. C., Dotsch, V., Baranski, T. J. & Bourne, H. R. (2001) J. Biol. Chem. 276, 3394-4000]. Recently, we showed that two Cys residues engineered near a proposed binding site in the C5a receptor on transmembrane helices III and VI can selectively and reversibly trap short Cys-containing 3-mer peptides derived from C5a by disulfide bond formation [Buck, E. A., Bourne, H. & Wells, J. A. (November 18, 2004) J. Biol. Chem., 10.1074/jbc.C400500200]. Here, a library of 10,000 compounds, each containing an exchangeable thiol, was screened to identify specific small-molecule mimics that block binding of C5a. Some of the selected compounds acted as agonists and were as potent as the natural C5a ligand, and some acted as antagonists. A residue near these compounds, Ile-116 in helix III, functions as a "gatekeeper" to modulate these effects. A small substitution, Ile-116-Ala, enhanced affinity for some compounds and allowed antagonists to function as agonists; a larger substitution, Ile-116-Trp, decreased affinity and agonism. Thus, subtle changes in either the structure of the ligand or the receptor at the site between helix III, VI, and VII can switch the receptor on or off. This ligand binding and activation site may be similarly positioned in other members of the chemokine receptor family. Selective ligand trapping by reversible disulfide formation may serve to nucleate the development of small-molecule mimics.
关于G蛋白偶联受体(GPCRs)信号传导机制的一个关键问题是,是什么引发了激动作用与拮抗作用。源自趋化因子补体片段5过敏毒素(C5a)的肽类似物,可以作为GPCR家族成员C5a受体的激动剂或拮抗剂[格伯,B.O.,孟,E.C.,多奇,V.,巴兰斯基,T.J.和伯恩,H.R.(2001年)《生物化学杂志》276,3394 - 4000]。最近,我们发现,在跨膜螺旋III和VI上C5a受体一个假定结合位点附近设计的两个半胱氨酸残基,能够通过形成二硫键选择性且可逆地捕获源自C5a的含半胱氨酸的短3肽[巴克,E.A.,伯恩,H.和韦尔斯,J.A.(2004年11月18日)《生物化学杂志》,10.1074/jbc.C400500200]。在此,对一个包含10000种化合物的文库进行了筛选,每种化合物都含有一个可交换的硫醇,以鉴定能阻断C5a结合的特定小分子模拟物。一些选定的化合物表现为激动剂,其效力与天然C5a配体相当,还有一些表现为拮抗剂。这些化合物附近的一个残基,螺旋III中的异亮氨酸 - 116,起到“守门人”的作用来调节这些效应。一个小的替换,异亮氨酸 - 116 - 丙氨酸,增强了对一些化合物的亲和力,并使拮抗剂发挥激动剂的作用;一个更大的替换,异亮氨酸 - 116 - 色氨酸,降低了亲和力和激动作用。因此,在螺旋III、VI和VII之间的位点上,配体或受体结构的细微变化都可以开启或关闭受体。这种配体结合和激活位点在趋化因子受体家族的其他成员中可能具有相似的定位。通过可逆二硫键形成进行的选择性配体捕获,可能有助于小分子模拟物的开发。